BlackRock Institutional Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

BlackRock Institutional Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$362M	Buy	4,373,022 +241,763	+6%	+$20.8M	0.05%	352
2016 Q3	$382M	Buy	4,131,259 +213,394	+5%	+$20.1M	0.06%	321
2016 Q2	$305M	Buy	3,917,865 +108,349	+3%	+$9.21M	0.05%	373
2016 Q1	$314M	Sell	3,809,516 -22,450	-0.6%	-$1.83M	0.05%	358
2015 Q4	$401M	Buy	3,831,966 +17,925	+0.5%	+$1.87M	0.07%	296
2015 Q3	$402M	Buy	3,814,041 +44,477	+1%	+$5.94M	0.07%	285
2015 Q2	$516M	Sell	3,769,564 -10,496	-0.3%	-$1.3M	0.08%	238
2015 Q1	$471M	Buy	3,780,060 +254,895	+7%	+$27M	0.07%	275
2014 Q4	$319M	Buy	3,525,165 +6,906	+0.2%	+$574K	0.05%	366
2014 Q3	$254M	Sell	3,518,259 -3,337	-0.1%	-$219K	0.04%	422
2014 Q2	$219M	Buy	3,521,596 +46,597	+1%	+$2.82M	0.04%	488
2014 Q1	$237M	Buy	3,474,999 +111,165	+3%	+$8.19M	0.04%	437
2013 Q4	$237M	Buy	3,363,834 +164,980	+5%	+$11.2M	0.04%	434
2013 Q3	$231M	Sell	3,198,854 -57,873	-2%	-$3.85M	0.04%	410
2013 Q2	$182M	Buy	+3,256,727	New	+$203M	0.04%	478

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock Institutional Trust's BMRN Position: Q4 2016 in Review

BlackRock Institutional Trust increased its BioMarin Pharmaceuticals (BMRN) stake by 5.9% in Q4 2016, buying an estimated $20.8M and bringing the position to 4,373,022 shares worth $362M. The position accounts for 0.05% of the portfolio, ranked #352.

BlackRock Institutional Trust first reported a position in BMRN in Q2 2013 and has held it in 15 quarters since. The position peaked at $516M in Q2 2015. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

BlackRock Institutional Trust held 4,373,022 shares of BioMarin Pharmaceuticals worth $362M as of Q4 2016.
BlackRock Institutional Trust bought 241,763 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $20.8M.
BioMarin Pharmaceuticals made up 0.05% of BlackRock Institutional Trust's portfolio in Q4 2016, its #352 holding.
BlackRock Institutional Trust first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's BioMarin Pharmaceuticals position peaked at $516M in Q2 2015.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.